MA60250B1 - 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile - Google Patents

1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Info

Publication number
MA60250B1
MA60250B1 MA60250A MA60250A MA60250B1 MA 60250 B1 MA60250 B1 MA 60250B1 MA 60250 A MA60250 A MA 60250A MA 60250 A MA60250 A MA 60250A MA 60250 B1 MA60250 B1 MA 60250B1
Authority
MA
Morocco
Prior art keywords
pyrrolidine
benzyloxy
difluoro
benzoyl
fluoro
Prior art date
Application number
MA60250A
Other languages
English (en)
French (fr)
Inventor
Teresa TARRAGÓ CLUA
Roger PRADES COSANO
Original Assignee
Accure Therapeutics, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accure Therapeutics, S.L. filed Critical Accure Therapeutics, S.L.
Publication of MA60250B1 publication Critical patent/MA60250B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MA60250A 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile MA60250B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382606 2020-07-07
EP21739678.7A EP4178945B1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
PCT/EP2021/068577 WO2022008477A1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Publications (1)

Publication Number Publication Date
MA60250B1 true MA60250B1 (fr) 2024-11-29

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
MA60250A MA60250B1 (fr) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Country Status (19)

Country Link
US (1) US12459891B2 (cg-RX-API-DMAC7.html)
EP (1) EP4178945B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628716B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230035604A (cg-RX-API-DMAC7.html)
CN (1) CN117545738A (cg-RX-API-DMAC7.html)
AU (1) AU2021303440B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185064A1 (cg-RX-API-DMAC7.html)
ES (1) ES2997164T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241527T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068953T2 (cg-RX-API-DMAC7.html)
IL (1) IL299035B2 (cg-RX-API-DMAC7.html)
MA (1) MA60250B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000261A (cg-RX-API-DMAC7.html)
RS (1) RS66215B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400460T1 (cg-RX-API-DMAC7.html)
TW (1) TWI893162B (cg-RX-API-DMAC7.html)
WO (1) WO2022008477A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213708B (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
EP2730571A1 (en) * 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
TW202216689A (zh) 2022-05-01
HUE068953T2 (hu) 2025-02-28
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
RS66215B1 (sr) 2024-12-31
IL299035A (en) 2023-02-01
US20230250058A1 (en) 2023-08-10
EP4178945A1 (en) 2023-05-17
IL299035B2 (en) 2026-07-01
JP2023533932A (ja) 2023-08-07
SMT202400460T1 (it) 2025-01-14
US12459891B2 (en) 2025-11-04
EP4178945C0 (en) 2024-08-28
TWI893162B (zh) 2025-08-11
KR20230035604A (ko) 2023-03-14
EP4178945B1 (en) 2024-08-28
JP7628716B2 (ja) 2025-02-12
ZA202213708B (en) 2024-04-24
CA3185064A1 (en) 2022-01-13
AU2021303440B2 (en) 2026-07-30
BR112023000335A2 (pt) 2023-01-31
AU2021303440A1 (en) 2023-02-02
CN117545738A (zh) 2024-02-09
MX2023000261A (es) 2023-04-13
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
MA59968B1 (fr) Composés de cyclobutyle dihydroquinoléine sulfonamide
MA63501B1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA29379B1 (fr) Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA29926B1 (fr) Derives de pyrazine
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
TN2009000138A1 (fr) Biaryl-ether-urees
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA59447B1 (fr) Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA28667B1 (fr) Derives d'acide benzimidazolonecarboxylique
MA49127B1 (fr) Dérivés d'indole n-substitués
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA63885A1 (fr) Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer